In this issue:
DAAVT safe, efficacious while awaiting LT
≥3 cups of coffee/day halves mortality risk in HIV-HCV
The essential role of monocytes in NK cell activation in HCV
Alcohol has an additive harmful effect in chronic HCV
A quantitative microarray antibody capture assay reveals HDV
Insights into the genetic diversity of HDV
Target Polo-like-kinase 1 for anti-HBV therapy?
Grazoprevir, ruzasvir, & uprifosbuvir for HCV after NS5A treatment failure
HBV behaves like a “stealth” virus
HCV infection activates HSCs to promote desmoplasia
Please login below to download this issue (PDF)